News Releases

December 20, 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

December 5, 2023

Indivior Prevails in Striking Representative Claims from UK Shareholder Action

November 9, 2023

Indivior Announces Q3 2023 Financial Results

October 23, 2023

Indivior Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results

October 11, 2023

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

August 21, 2023

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

July 27, 2023

Indivior Announces H1 and Q2 2023 Financial Results

June 14, 2023

Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

June 12, 2023

Indivior to Commence Trading on Nasdaq

June 2, 2023

Indivior Reaches Agreement with States’ Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims